Sort

Search

07/02/2025 Sprinkler irrigation of urban sport fields as a potential source of Legionella
Bosch, G, Queralt, A, Valero, N, Lleó, T, Portolés, C, Vargas-Leguas, H, Parra, E, Gonzalez, R, Rius, C, Gómez-Gutiérrez, A. Sprinkler irrigation of urban sport fields as a potential source of Legionella. Archives of Environmental & Occupational Health. 2025; 80(1-2)DOI:10.1080/19338244.2025.2451903. PMID:39874031. IF:0.900(Q4/9D).
04/02/2025 Anterior clinoid process metastasis with sudden loss of vision: role of emergency optic nerve decompression
Rico-Pereira, M, Muñoz-Hernández, F. Anterior clinoid process metastasis with sudden loss of vision: role of emergency optic nerve decompression. Egyptian Journal Of Neurosurgery. 2025; 40(1)DOI:10.1186/s41984-025-00371-3. PMID:. IF:(Q/D).
04/02/2025 Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study
Bastos-Oreiro, M, Iacoboni, G, Garcés, VN, Caballero, AC, Martínez, N, Delgado, J, Balaguer, A, Kwon, M, de Villambrosia, S, Hernani, R, Jimenez-Ubieto, A, Bailen, R, Zaberio, I, García-Sancho, A, Barba, P. Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study. Hemasphere. 2025; 9(2)DOI:10.1002/hem3.70077. PMID:39906687. IF:14.600(Q1/1D).
04/02/2025 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini, A, Brunetti, L, Di Fazio, GR, Garbo, E, Pinato, DJ, Naidoo, J, Katz, A, Loza, M, Neal, JW, Genova, C, Gettinger, S, Kim, SY, Jayakrishnan, R, El Zarif, T, Russano, M, Pecci, F, Di Federico, A, Awad, M, Alessi, J, Montrone, M, Owen, DH, Signorelli, D, Fidler, MJ, Li, MJ, Camerini, A, De Giglio, A, Young, L, Vincenzi, B, Metro, G, Passiglia, F, Yendamuri, S, Guida, A, Ghidini, M, Awosika, NO, Napolitano, A, Fulgenzi, CAM, Grisanti, S, Grossi, F, D'Incecco, A, Josephides, E, Van Hemelrijck, M, Russo, A, Gelibter, A, Spinelli, G, Verrico, M, Tomasik, B, Giusti, R, Newsom-Davis, T, Bria, E, Sebastian, M, Rost, M, Forster, M, Mukherjee, U, Landi, L, Mazzoni, F, Aujayeb, A, Dupont, M, Curioni-Fontecedro, A, Chiari, R, Pantano, F, Morabito, A, Leonetti, A, Friedlaender, A, Addeo, A, Zoratto, F, De Tursi, M, Cantini, L, Roca, E, Mountzios, G, Della Gravara, L, Kalvapudi, S, Inno, A, Bironzo, P, Barros, RD, O'Reilly, D, Bell, J, Karapanagiotou, E, Monnet, I, Baena, J, Macerelli, M, Majem, M, Agustoni, F, Cortinovis, DL, Tonini, G, Minuti, G, Bennati, C, Mezquita, L, Gorría, T, Servetto, A, Beninato, T, Lo Russo, G, Rogado, J, Moliner, L, Biello, F, Nana, FA, Dingemans, AM, Aerts, JGJ, Ferrara, R, Torri, V, Abu Hejleh, T, Takada, K, Naqash, AR, Garassino, M, Peters, S, Wakelee, H, Nassar, AH, Ricciuti, B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal for ImmunoTherapy of Cancer. 2025; 13(2)DOI:10.1136/jitc-2024-010674. PMID:39904562. IF:10.600(Q1/1D).